Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.

Sun Y, Wang S, Yang H, Wu J, Li S, Qiao G, Wang S, Wang X, Zhou X, Osada T, Hobeika A, Morse MA, Ren J, Lyerly HK.

Immunotherapy. 2019 Aug;11(11):953-966. doi: 10.2217/imt-2019-0055. Epub 2019 Jun 13.

PMID:
31192764
2.

Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.

Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan F, Li Y, Wang S, Morse MA, Hobeika A, Ren J, Lyerly HK.

Clin Breast Cancer. 2019 Apr 16. pii: S1526-8209(19)30213-7. doi: 10.1016/j.clbc.2019.04.001. [Epub ahead of print]

PMID:
31101455
3.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty.

Eur J Cancer. 2019 Jun;114:128-136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3.

PMID:
31060925
4.

Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.

Wang X, Wang S, Morse MA, Jiang N, Zhao Y, Song Y, Zhou L, Huang H, Zhou X, Hobeika A, Ren J, Lyerly HK.

J Thromb Thrombolysis. 2019 May;47(4):505-511. doi: 10.1007/s11239-019-01844-7.

PMID:
30903459
5.

Challenges with Novel Clinical Trial Designs: Master Protocols.

Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM.

Clin Cancer Res. 2019 Apr 1;25(7):2049-2057. doi: 10.1158/1078-0432.CCR-18-3544. Epub 2019 Jan 29.

PMID:
30696689
6.

Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.

Wang J, Ren XR, Piao H, Zhao S, Osada T, Premont RT, Mook RA Jr, Morse MA, Lyerly HK, Chen W.

Biochem J. 2019 Feb 8;476(3):535-546. doi: 10.1042/BCJ20180385.

PMID:
30635359
7.

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC.

Clin Cancer Res. 2019 May 1;25(9):2725-2736. doi: 10.1158/1078-0432.CCR-18-3102. Epub 2019 Jan 11.

PMID:
30635338
8.

Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.

Mook RA Jr, Wang J, Ren XR, Piao H, Lyerly HK, Chen W.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):317-321. doi: 10.1016/j.bmcl.2018.11.022. Epub 2018 Nov 12.

PMID:
30551901
9.

Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers.

Lyerly HK, Ren J, Canetta R, Kim GH, Nagai S, Yamaguchi T, Hatogai K, Katayama H, Da Rocha Dias S, McManus D, Soltys K, Yang Z, Olopade O, Goodman N, Reaman G, Gross T.

J Glob Oncol. 2018 Dec;4:1-11. doi: 10.1200/JGO.18.00092.

PMID:
30521412
10.

Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.

Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, Zhao L, Morse MA, Hobeika A, Song J, Yi X, Xia X, Ren J, Lyerly HK.

Clin Cancer Res. 2019 Mar 1;25(5):1494-1504. doi: 10.1158/1078-0432.CCR-18-2360. Epub 2018 Dec 4.

PMID:
30514775
11.

Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.

Lyerly HK, Osada T, Hartman ZC.

Clin Cancer Res. 2019 Jan 1;25(1):9-11. doi: 10.1158/1078-0432.CCR-18-2819. Epub 2018 Oct 30.

PMID:
30377197
12.

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N, Zhou L, Huang H, Zhao J, Morse MA, Hobeika A, Ren J, Lyerly HK.

Clin Transl Oncol. 2019 Jun;21(6):721-728. doi: 10.1007/s12094-018-1968-3. Epub 2018 Oct 29.

PMID:
30374838
13.

Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.

Wang J, Mook RA Jr, Ren XR, Zhang Q, Jing G, Lu M, Spasojevic I, Lyerly HK, Hsu D, Chen W.

Bioorg Med Chem. 2018 Nov 1;26(20):5435-5442. doi: 10.1016/j.bmc.2018.09.016. Epub 2018 Sep 17.

PMID:
30274939
14.

Philanthropy Profile: Protecting North Carolina's Health by Investing in a Healthy Environment.

Blotnick J, Lyerly HK.

N C Med J. 2018 Sep-Oct;79(5):337-338. doi: 10.18043/ncm.79.5.337. No abstract available.

15.

The Health Impacts of Environmental Policy: The North Carolina Clean Smokestacks Act.

Kravchenko J, Lyerly HK, Ross W.

N C Med J. 2018 Sep-Oct;79(5):329-333. doi: 10.18043/ncm.79.5.329.

16.

Health and the Environment in North Carolina.

Lyerly HK, Peden DB.

N C Med J. 2018 Sep-Oct;79(5):302-305. doi: 10.18043/ncm.79.5.302. Erratum in: N C Med J. 2018 Nov-Dec;79(6):407.

17.

The Impact of Coal-Powered Electrical Plants and Coal Ash Impoundments on the Health of Residential Communities.

Kravchenko J, Lyerly HK.

N C Med J. 2018 Sep-Oct;79(5):289-300. doi: 10.18043/ncm.79.5.289. Review.

18.

Mortality and Health Outcomes in North Carolina Communities Located in Close Proximity to Hog Concentrated Animal Feeding Operations.

Kravchenko J, Rhew SH, Akushevich I, Agarwal P, Lyerly HK.

N C Med J. 2018 Sep-Oct;79(5):278-288. doi: 10.18043/ncm.79.5.278.

19.

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.

Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, Diniz MA, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK.

Breast Cancer Res. 2018 Aug 9;20(1):90. doi: 10.1186/s13058-018-1023-x.

20.

White paper on microbial anti-cancer therapy and prevention.

Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G.

J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3.

21.

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.

Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu CX, Agarwal P, Korman AJ, Morse MA, Gouin K, Knott SRV, Lyerly HK, Hartman ZC.

Oncoimmunology. 2018 Jan 19;7(5):e1421891. doi: 10.1080/2162402X.2017.1421891. eCollection 2018.

22.

CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.

Zhou X, Qiao G, Wang X, Song Q, Morse MA, Hobeika A, Gwin WR, Ren J, Lyerly HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):365-372. doi: 10.1007/s00280-017-3500-9. Epub 2017 Dec 14.

PMID:
29242966
23.

In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.

Osada T, Kaneko K, Gwin WR, Morse MA, Hobeika A, Pogue BW, Hartman ZC, Hughes PF, Haystead T, Lyerly HK.

Clin Cancer Res. 2017 Dec 15;23(24):7531-7542. doi: 10.1158/1078-0432.CCR-17-1453. Epub 2017 Oct 9.

24.

Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study.

Song Q, Ren J, Zhou X, Wang X, Song G, Hobeika A, Yuan Y, Lyerly HK.

Cytotherapy. 2018 Jan;20(1):126-133. doi: 10.1016/j.jcyt.2017.08.018. Epub 2017 Oct 4.

PMID:
28988693
25.

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.

Osada T, Morse MA, Hobeika A, Diniz MA, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK.

Oncoimmunology. 2017 Apr 12;6(6):e1315495. doi: 10.1080/2162402X.2017.1315495. eCollection 2017.

26.

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.

Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK.

Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13.

27.

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Ren J, Gwin WR, Zhou X, Wang X, Huang H, Jiang N, Zhou L, Agarwal P, Hobeika A, Crosby E, Hartman ZC, Morse MA, H Eng K, Lyerly HK.

Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017.

28.

Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.

Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR.

Carcinogenesis. 2017 Mar 1;38(3):252-260. doi: 10.1093/carcin/bgx003.

29.

Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness.

Snyder JC, Rochelle LK, Ray C, Pack TF, Bock CB, Lubkov V, Lyerly HK, Waggoner AS, Barak LS, Caron MG.

J Biol Chem. 2017 Apr 28;292(17):7208-7222. doi: 10.1074/jbc.M116.756635. Epub 2017 Mar 8.

30.

A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.

Crowe LB, Hughes PF, Alcorta DA, Osada T, Smith AP, Totzke J, Loiselle DR, Lutz ID, Gargesha M, Roy D, Roques J, Darr D, Lyerly HK, Spector NL, Haystead TAJ.

ACS Chem Biol. 2017 Apr 21;12(4):1047-1055. doi: 10.1021/acschembio.7b00006. Epub 2017 Feb 23.

PMID:
28103010
31.

X-Ray Psoralen Activated Cancer Therapy (X-PACT).

Oldham M, Yoon P, Fathi Z, Beyer WF, Adamson J, Liu L, Alcorta D, Xia W, Osada T, Liu C, Yang XY, Dodd RD, Herndon JE 2nd, Meng B, Kirsch DG, Lyerly HK, Dewhirst MW, Fecci P, Walder H, Spector NL.

PLoS One. 2016 Sep 1;11(9):e0162078. doi: 10.1371/journal.pone.0162078. eCollection 2016.

32.

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.

Quiroga D, Lyerly HK, Morse MA.

Curr Treat Options Oncol. 2016 Aug;17(8):41. doi: 10.1007/s11864-016-0414-4. Review.

PMID:
27315067
33.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

34.

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Vaidyanathan G, McDougald D, Choi J, Koumarianou E, Weitzel D, Osada T, Lyerly HK, Zalutsky MR.

J Nucl Med. 2016 Jun;57(6):967-73. doi: 10.2967/jnumed.115.171306. Epub 2016 Feb 18.

35.

The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.

Song Q, Zhou X, Yu J, Dong N, Wang X, Yang H, Ren J, Lyerly HK.

Sci Rep. 2015 Nov 25;5:16775. doi: 10.1038/srep16775.

36.

Checkpoint blockade in combination with cancer vaccines.

Morse MA, Lyerly HK.

Vaccine. 2015 Dec 16;33(51):7377-7385. doi: 10.1016/j.vaccine.2015.10.057. Epub 2015 Oct 17. Review.

PMID:
26482147
37.

The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.

Song QK, Ren J, Zhou XN, Wang XL, Song GH, Di LJ, Yu J, Hobeika A, Morse MA, Yuan YH, Yang HB, Lyerly HK.

Oncotarget. 2015 Dec 1;6(38):41350-9. doi: 10.18632/oncotarget.5534.

38.

Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.

Zhou X, Wang X, Song Q, Yang H, Zhu X, Yu J, Song G, Di L, Ren J, Shao H, Lyerly HK.

Int J Clin Pharmacol Ther. 2015 Nov;53(11):914-22. doi: 10.5414/CP202391.

PMID:
26396136
39.

Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.

Mook RA Jr, Wang J, Ren XR, Chen M, Spasojevic I, Barak LS, Lyerly HK, Chen W.

Bioorg Med Chem. 2015 Sep 1;23(17):5829-38. doi: 10.1016/j.bmc.2015.07.001. Epub 2015 Aug 10.

40.

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, Di L, Song G, Che L, Jia J, Zhou X, Yang H, Lyerly HK.

Clin Transl Oncol. 2016 Jan;18(1):82-7. doi: 10.1007/s12094-015-1339-2. Epub 2015 Aug 13.

PMID:
26266766
41.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

42.

Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Kravchenko J, Corsini E, Williams MA, Decker W, Manjili MH, Otsuki T, Singh N, Al-Mulla F, Al-Temaimi R, Amedei A, Colacci AM, Vaccari M, Mondello C, Scovassi AI, Raju J, Hamid RA, Memeo L, Forte S, Roy R, Woodrick J, Salem HK, Ryan EP, Brown DG, Bisson WH, Lowe L, Lyerly HK.

Carcinogenesis. 2015 Jun;36 Suppl 1:S111-27. doi: 10.1093/carcin/bgv033. Epub 2015 May 22. Review.

43.

Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies.

Song QK, Wang XL, Zhou XN, Yang HB, Li YC, Wu JP, Ren J, Lyerly HK.

Oncologist. 2015 Jul;20(7):773-9. doi: 10.1634/theoncologist.2014-0351. Epub 2015 May 22.

44.

Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan.

Lyerly HK, Fawzy MR, Aziz Z, Nair R, Pramesh CS, Parmar V, Parikh PM, Jamal R, Irumnaz A, Ren J, Stockler MR, Abernethy AP.

Oncologist. 2015 May;20(5):532-8. doi: 10.1634/theoncologist.2014-0213. Epub 2015 Apr 17.

45.

Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Ren XR, Wang J, Osada T, Mook RA Jr, Morse MA, Barak LS, Lyerly HK, Chen W.

Breast Cancer Res. 2015 Feb 15;17:20. doi: 10.1186/s13058-015-0528-9.

46.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
47.

Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.

Zhao YJ, Jiang N, Song QK, Wu JP, Song YG, Zhang HM, Chen F, Zhou L, Wang XL, Zhou XN, Yang HB, Ren J, Lyerly HK.

Asian Pac J Cancer Prev. 2015;16(6):2419-23.

48.

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.

Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK.

Cancer Immunol Immunother. 2015 Jun;64(6):677-88. doi: 10.1007/s00262-015-1671-y. Epub 2015 Mar 6.

PMID:
25742933
49.

Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis.

Kravchenko J, Berry M, Arbeev K, Lyerly HK, Yashin A, Akushevich I.

Lung Cancer. 2015 Apr;88(1):85-93. doi: 10.1016/j.lungcan.2015.01.006. Epub 2015 Jan 17.

50.

Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like membrane protrusions.

Snyder JC, Rochelle LK, Marion S, Lyerly HK, Barak LS, Caron MG.

J Cell Sci. 2015 Mar 15;128(6):1230-40. doi: 10.1242/jcs.166322. Epub 2015 Feb 4.

Supplemental Content

Loading ...
Support Center